SCHEMBL5543183

SCHEMBL5543183

CC(CCCN[C]=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
MMP7 P09237 1/20 0.36
PDE2A O00408 1/20 0.36
LMNA P02545 5/20 0.35
MEN1 O00255 4/20 0.35
KMT2A Q03164 4/20 0.35
FFAR1 O14842 3/20 0.35
NPC1 O15118 2/20 0.35
CYP2D6 P10635 2/20 0.35
CYP2C19 P33261 2/20 0.35
MTOR P42345 2/20 0.35
RAB9A P51151 2/20 0.35
CYP3A4 P08684 2/20 0.35
SLC6A2 P23975 2/20 0.35
HTR2C P28335 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5536705 0.82 ALDH1A1 (0.41) PDE2AALDH1A1HPGD
SCHEMBL5543392 0.80 HTR2A (0.44) LMNAMEN1KMT2ANPC1CYP2D6
SCHEMBL5543187 0.79 CA1 (0.38) CA1CA2MMP7PDE2ALMNA
SCHEMBL1044947 0.78 PDE2A (0.41) CA1CA2PDE2ALMNAFFAR1
SCHEMBL2097126 0.77 PDE2A (0.36) CA1CA2PDE2ALMNAFFAR1
SCHEMBL16442485 0.76 PDE2A (0.46) CA1CA2PDE2ALMNAMEN1
SCHEMBL20789414 0.76 PDE2A (0.46) CA1CA2PDE2ALMNAMEN1
SCHEMBL6002598 0.76 PDE2A (0.46) CA1CA2PDE2ALMNAMEN1
SCHEMBL24394438 0.74 PDE2A (0.45) CA1CA2PDE2ALMNAMEN1
SCHEMBL2095472 0.74 PDE2A (0.41) CA1CA2PDE2ALMNAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CA1 3493/4885CA2 1853/4885MMP7 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.